Pulmonary blastoma with renal metastasis responds to sorafenib.
Biphasic pulmonary blastoma is a rare malignancy of the lung composed of proliferating epithelial and mesenchymal cells with a high vessel density at the tumor periphery. We report a rare case of renal metastasis of biphasic pulmonary blastoma that responded to sorafenib, an oral multikinase inhibitor. After 2 months of treatment with sorafenib, the renal tumor size decreased sufficiently to allow a safe laparoscopic radical nephrectomy. We believe that further studies are warranted to confirm the possible effects of sorafenib on pulmonary blastomas.
Mulamalla
Keerthi
K
Division of Hematology, Oncology and Transplantation, University of Minnesota Medical School, Minneapolis, Minnesota, USA.
Truskinovsky
Alexander M
AM
Dudek
Arkadiusz Z
AZ
D000284:Administration, Oral; D000328:Adult; D001557:Benzenesulfonates / Q000008:administration & dosage*; D001707:Biopsy, Needle; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000556:secondary* / Q000601:surgery; D008175:Lung Neoplasms / Q000473:pathology* / Q000628:therapy; D009367:Neoplasm Staging; D009392:Nephrectomy / Q000379:methods; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011013:Pneumonectomy / Q000379:methods; D018202:Pulmonary Blastoma / Q000473:pathology / Q000556:secondary* / Q000628:therapy; D011725:Pyridines / Q000008:administration & dosage*; D018570:Risk Assessment; D000077157:Sorafenib; D016896:Treatment Outcome
D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib